HAMBURG, Germany, May 6, 2009 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) will report its financial results for the first quarter of 2009 on Tuesday, May 12, 2009.
The Company is going to hold a conference call to discuss the results:
Conference call details:
Date: Tuesday, May 12, 2009
Time: 09.30 a.m. CEST
08.30 a.m. BST
03.30 a.m. U.S. time (East Coast)
From Europe: +49.(0)69.5007 1308 (Germany)
+44.(0)20.7806 1955 (UK)
From the U.S.: +1.718.354 1388
Access Code: 8354186
A simultaneous slide presentation for participants dialing in via phone is available at www.equitystory.com, password: evotec0509.
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialing +49.(0)69.22222 0418 (Germany) or +44.(0)20.7806 1970 (UK) and in the U.S. by +1.718.354 1112. The access code is 8354186#. The on-demand version of the webcast will be available on our website: www.evotec.com - Investors - Financial Reports.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies.
Evotec has long-term discovery alliances with partners including Boehringer Ingel-heim, CHDI, Novartis, Ono Pharmaceutical and Roche. The Company has a P2X7 antagonist for the treatment of inflammatory diseases in clinical development and a series of preclinical compounds and development partnerships, including a strategic alliance with Roche for EVT 101, a subtype selective NMDA receptor antagonist, for use in treatment-resistant depression.